Telmisartan boosts olaparib cancer therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Telmisartan enhances the cancer-killing effect of olaparib in preclinical studies, even in tumors without homologous recombination DNA repair defects, broadening the potential patient population for PARP inhibitor therapy.
- Dartmouth Cancer Center researchers found that telmisartan increases type I interferon production, a key immune activation mechanism that helps the body recognize and attack cancer cells when combined with olaparib.
- Telmisartan uniquely lowers tumor PD-L1 levels among angiotensin II receptor blockers, potentially reducing cancer’s ability to evade immune detection during therapy.
- Tyler J. Curiel leads two active clinical trials testing telmisartan with olaparib—one in metastatic castration-resistant prostate cancer and another in platinum-resistant ovarian cancer—after observing an exceptional early patient response.
- Olaparib’s efficacy is typically limited to BRCA-mutant tumors, but telmisartan enables it to work in homologous recombination-proficient cancers, addressing a major limitation of current PARP inhibitor use.
Why it matters: Patients with non-BRCA cancers who previously couldn’t benefit from PARP inhibitors may now have a viable treatment path, as telmisartan repurposes an inexpensive, widely available drug to overcome tumor resistance and boost immune response—potentially accelerating clinical adoption due to its established safety profile.
